Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Huang, Wen Yen ^a   Jen, Yee Min ^a   Chen, Chang Ming ^a   Su, Yu Fu ^a   Lin, Chun Shu ^a   Lin, Yaoh Shiang ^a   Chang, Ying Nan ^a   Chao, Hsing Lung ^a   Lin, Kuen Tze ^a   Chang, Li Ping ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPARATIVE STUDY; DYSPHAGIA; FEMALE; FIBROSIS; FISTULA; FOLLOW UP; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHARYNGITIS; PHARYNGOCUTANEOUS FISTULA; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; VOCAL CORD PARALYSIS; WEIGHT REDUCTION; WOUND INFECTION; XEROSTOMIA; HYPOPHARYNX TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION RESPONSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77952101627     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-37     Document Type: Article

References (28)

1. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996, 88:890-99. 10.1093/jnci/88.13.890, 8656441.
2. Kim S, Wu HG, Heo DS, Kim KH, Sung MW, Park CI. Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. Head Neck 2001, 23:713-17. 10.1002/hed.1101, 11505479.
3. Lajtman Z, Manestar D. A comparison of surgery and radiotherapy in the management of advanced pyriform fossa carcinoma. Clin Otolaryngol Allied Sci 2001, 26:59-61. 10.1046/j.1365-2273.2001.00430.x, 11298170.
4. Zelefsky MJ, Kraus DH, Pfister DG, Raben A, Shah JP, Strong EW, Spiro RH, Bosl GJ, Harrison LB. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck 1996, 18:405-11. 10.1002/(SICI)1097-0347(199609/10)18:5<405::AID-HED3>3.0.CO;2-9, 8864731.
5. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996, 14:838-47.
6. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14. 10.1016/j.radonc.2009.04.014, 19446902.
7. Gregoire V, De Neve W, Eisbruch A, Lee N, Weyngaert D, Van Gestel D. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist 2007, 12:555-64. 10.1634/theoncologist.12-5-555, 17522243.
8. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002, 53:12-22. 10.1016/S0360-3016(02)02859-6, 12007936.
9. Eisbruch A, Ship JA, Dawson LA, Kim HM, Bradford CR, Terrell JE, Chepeha DB, Teknos TN, Hogikyan ND, Anzai Y, Marsh LH, Ten RK, Wolf GT. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg 2003, 27:832-37. 10.1007/s00268-003-7105-6, 14509515.
10. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer 2000, 90:92-103. 10.1002/(SICI)1097-0215(20000420)90:2<92::AID-IJC5>3.0.CO;2-9, 10814959.
11. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009, 73:424-32.
12. de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2006, 64:363-73.
13. Rosenbluth BD, Serrano V, Happersett L, Shaha AR, Tuttle RM, Narayana A, Wolden SL, Rosenzweig KE, Chong LM, Lee NY. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 2005, 63:1419-26. 10.1016/j.ijrobp.2005.05.043, 16154712.
14. Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2007, 69:459-68.
15. Studer G, Lutolf UM, Davis JB, Glanzmann C. IMRT in hypopharyngeal tumors. Strahlenther Onkol 2006, 182:331-35. 10.1007/s00066-006-1556-2, 16703288.
16. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98. 10.1200/JCO.2003.01.008, 12506176.
17. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006, 24:2618-23. 10.1200/JCO.2005.04.7225, 16763274.
18. Lee NY, de Arruda FF, Puri DR, Wolden SL, Narayana A, Mechalakos J, Venkatraman ES, Kraus D, Shaha A, Shah JP, Pfister DG, Zelefsky MJ. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006, 66:966-74.
19. Veldeman L, Madani I, Hulstaert F, De Meerleer G, Mareel M, De Neve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol 2008, 9:367-75. 10.1016/S1470-2045(08)70098-6, 18374290.
20. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, Eliachar I, Strome M, Larto MA. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000, 88:876-83. 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO;2-Y, 10679658.
21. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Acta Oncol 2009, 48:431-39. 10.1080/02841860802372272, 18781445.
22. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92:744-51. 10.1016/j.ygyno.2003.11.048, 14984936.
23. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350:1937-44. 10.1056/NEJMoa032646, 15128893.
24. Miyaguchi M, Olofsson J, Hellquist HB. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol Allied Sci 1991, 16:466-69. 10.1111/j.1365-2273.1991.tb01041.x, 1742894.
25. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, Demard F, Milano G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993, 11:1873-78.
26. Rubin J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998, 90:824-32. 10.1093/jnci/90.11.824, 9625170.
27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-78. 10.1056/NEJMoa053422, 16467544.
28. Ang KK. Phase III randomized study of concurrent accelerated fractionated radiotherapy and cisplatin with versus without cetuximab in patients with stage III or IV squamous cell carcinoma of the oropharynx, hypopharynx, or larynx. Protocol RTOG-0522. Accessed January 25, 2007., http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=458049andvers ion=HealthProfessionalandprotocolsearchid=4920187